ODYSSEY, a global program to evaluate SAR236553 REGN727, a potential first-in-class PCSK9 inhibitor, will comprise over ten clinical trials and will include mor (Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering...